Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro.

Détails

ID Serval
serval:BIB_B5A1C7ABFC3D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro.
Périodique
Scientific reports
Auteur(s)
Cagno V., Medaglia C., Cerny A., Cerny T., Zwygart A.C., Cerny E., Tapparel C.
ISSN
2045-2322 (Electronic)
ISSN-L
2045-2322
Statut éditorial
Publié
Date de publication
12/07/2021
Peer-reviewed
Oui
Volume
11
Numéro
1
Pages
14295
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
Methylene blue is an FDA (Food and Drug Administration) and EMA (European Medicines Agency) approved drug with an excellent safety profile. It displays broad-spectrum virucidal activity in the presence of UV light and has been shown to be effective in inactivating various viruses in blood products prior to transfusions. In addition, its use has been validated for methemoglobinemia and malaria treatment. In this study, we first evaluated the virucidal activity of methylene blue against influenza virus H1N1 upon different incubation times and in the presence or absence of light activation, and then against SARS-CoV-2. We further assessed the therapeutic activity of methylene blue by administering it to cells previously infected with SARS-CoV-2. Finally, we examined the effect of co-administration of the drug together with immune serum. Our findings reveal that methylene blue displays virucidal preventive or therapeutic activity against influenza virus H1N1 and SARS-CoV-2 at low micromolar concentrations and in the absence of UV-activation. We also confirm that MB antiviral activity is based on several mechanisms of action as the extent of genomic RNA degradation is higher in presence of light and after long exposure. Our work supports the interest of testing methylene blue in clinical studies to confirm a preventive and/or therapeutic efficacy against both influenza virus H1N1 and SARS-CoV-2 infections.
Mots-clé
Animals, COVID-19/drug therapy, COVID-19/genetics, COVID-19/virology, Chlorocebus aethiops, Humans, Influenza, Human/drug therapy, Influenza, Human/genetics, Influenza, Human/virology, Methylene Blue/pharmacology, SARS-CoV-2/drug effects, SARS-CoV-2/pathogenicity, Ultraviolet Rays/adverse effects, Vero Cells, Virus Inactivation/drug effects, Virus Inactivation/radiation effects, Virus Replication/drug effects, Virus Replication/radiation effects
Pubmed
Web of science
Open Access
Oui
Création de la notice
15/07/2021 14:18
Dernière modification de la notice
07/08/2021 5:37
Données d'usage